Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 154

Sort by

Sort Order Select

Journal Articles

Core-binding factor fusion downregulation of ADAR2 RNA editing contributes to AML leukemogenesis

Blood (2023) 141 (25): 3078–3090.

https://doi.org/10.1182/blood.2022015830

Published: 2023

Includes: Supplemental data

Journal Articles

A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia

Blood (2023) 141 (22): 2738–2755.

https://doi.org/10.1182/blood.2022017295

Published: 2023

Includes: Supplemental data

Journal Articles

Systematic Functional Characterization for Loss of Function Events Cooperating with TP53 Loss in High-Risk 17p13(del) Multiple Myeloma

Phaik Ju Teoh, Ricardo De Matos Simoes, Tae-Hoon Chung, Mick Lee, Olga Dashevsky, Shizuka Yamano, Roger Foo, Wee Joo Chng, Constantine S. Mitsiades

Blood (2022) 140 (Supplement 1): 7110–7111.

https://doi.org/10.1182/blood-2022-159316

Published: 2022

Journal Articles

Elucidating the Role of ADAR1 in Regulating Immunotherapeutic Response in Multiple Myeloma

Mun Yee Koh, Phaik Ju Teoh, Tae-Hoon Chung, Leilei Chen, Wee Joo Chng

Blood (2022) 140 (Supplement 1): 7084–7085.

https://doi.org/10.1182/blood-2022-158848

Published: 2022

Journal Articles

Daratumumab in Multiple Myeloma - a Nationwide Real-World Experience from Singapore

Allison Ching Yee Tso, Wee Joo Chng, Yeow Tee Goh, Melissa Ooi, Yunxin Chen, Chandramouli Nagarajan, Daryl Tan, Kiat Hoe Ong

Blood (2022) 140 (Supplement 1): 12596–12597.

https://doi.org/10.1182/blood-2022-157940

Published: 2022

Journal Articles

Single Cell Multi-Omic Profiling of Multiple Myeloma with t(4;14) Identifies a T-Cell Population That Correlates with Clinical Outcomes

Sanjay de Mel, Jonathan Adam Scolnick, Chern Han Yong, Stacy Xu, Cinnie Yentia Soekojo, Fangfang Song, Melissa Ooi, Wee Joo Chng

Blood (2022) 140 (Supplement 1): 4336–4337.

https://doi.org/10.1182/blood-2022-164465

Published: 2022

Journal Articles

How Does Treatment Intolerance Affect Survival in Patients with Multiple Myeloma (MM)?

Dr. Maryam Alomran, Cameron Wellard, Pin-Yen Chen, Elizabeth M. Moore, Wee Joo Chng

Blood (2022) 140 (Supplement 1): 10075–10076.

https://doi.org/10.1182/blood-2022-164613

Published: 2022

Journal Articles

Myeloma Treatment Patterns and Clinical Outcomes in the Asia-Pacific: Updated Results from the Asia-Pacific Myeloma and Related Diseases Registry

Naomi Aoki, Pin-Yen Chen, Elizabeth M. Moore, Erica M. Wood, Cameron Wellard, Zoe McQuilten, Gin Gin Gan, Wee Joo Chng, Andrew Spencer

Blood (2022) 140 (Supplement 1): 13293–13294.

https://doi.org/10.1182/blood-2022-165798

Published: 2022

Journal Articles

Pre-Clinical Evaluation of a Camsirubicin Analog Mnpr-202 in Diffuse Large B Cell Lymphoma

Julie A.S. Lammers, Hoang Mai Phuong, Charmaine Ong, Min Liu, Patrick Jaynes, Raji R. Nair, Wee Joo Chng, Chandler D. Robinson, Anand D. Jeyasekharan

Blood (2022) 140 (Supplement 1): 5998–5999.

https://doi.org/10.1182/blood-2022-168761

Published: 2022

Journal Articles

A Non-Coding Variant in LOC105371512 Confers Susceptibility to Bleomycin-Induced Lung Injury

Blood (2022) 140 (Supplement 1): 4542–4544.

https://doi.org/10.1182/blood-2022-169416

Published: 2022

Journal Articles

Efficacy of Frontline Treatments for Newly Diagnosed Transplant-Ineligible Multiple Myeloma, a Network Meta-Analysis

Maggie Wong, Chen Wang, Cinnie Yentia Soekojo, Hung Chew Wong, Sanjay De Mel, Melissa Ooi, Miny Samuel, Yu Yang Soon, Wee Joo Chng

Blood (2022) 140 (Supplement 1): 4345–4346.

https://doi.org/10.1182/blood-2022-165849

Published: 2022

Journal Articles

Real World Treatment Outcomes for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant in Different Income Countries within Asia Pacific Region

Chin Sum Cheong, Sen Mui Tan, Soo Chin Ng, Tee Chuan Ong, Sharifah Shahnaz Syed Abd Kadir, Kim Wah Ho, Alan Teh, Haris Abdul Rahman, Ping Chong Bee, Naomi Aoki, Pin-Yen Chen, Erica M. Wood, Andrew Spencer, Elizabeth M. Moore, Wee Joo Chng, Gin Gin Gan

Blood (2022) 140 (Supplement 1): 12541–12543.

https://doi.org/10.1182/blood-2022-164888

Published: 2022

Journal Articles

New immunotherapeutic target in myeloma

Wee Joo Chng

Blood (2022) 139 (16): 2417–2418.

https://doi.org/10.1182/blood.2022015481

Published: 2022

Journal Articles

Evaluating Front Line Treatment Regimens for Waldenstrom Macroglobulinaemia: A Systematic Review and Meta-Analysis

Wee Lee William Chan, Vanessa CL Chong, Ian JY Wee, Anand Jeyasekharan, Michelle Poon, Hian Li Esther Chan, Joanne Lee, Yen Lin Chee, Wee-Joo Chng, Miny Samuel, Sanjay de Mel

Blood (2021) 138 (Supplement 1): 1358.

https://doi.org/10.1182/blood-2021-150678

Published: 2021

Journal Articles

Mapbatch: Conservative Batch Normalization for Single Cell RNA-Sequencing Data Enables Discovery of Rare Cell Populations in a Multiple Myeloma Cohort

Chern Han Yong, Shawn Hoon, Sanjay De Mel, Stacy Xu, Jonathan Adam Scolnick, Xiaojing Huo, Michael Lovci, Wee Joo Chng, Limsoon Wong

Blood (2021) 138 (Supplement 1): 2954.

https://doi.org/10.1182/blood-2021-150089

Published: 2021

Journal Articles

Single-Cell Multi-Omic Analysis Uncovers Comprised Immune Function and Primary Resistance Mechanism in Acute Myeloid Leukemia

Jianbiao Zhou, Jonathan Adam Scolnick, Stacy Xu, Melissa Ooi, Priscella Shirley Chia, Sabrina Hui-Min Toh, Kalpnaa Balan, Michael Lovci, Tuan Zea Tan, Jen Wei Ying, Chin-Hin NG, Wee-Joo Chng

Blood (2021) 138 (Supplement 1): 378.

https://doi.org/10.1182/blood-2021-149022

Published: 2021

Journal Articles

Lenalidomide Compared to Ixazomib Maintenance in Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis

Eunice Lai, Yu Yang Soon, Ainsley Ryan Yan Bin Lee, Shi Yin Wong, Cinnie Yentia Soekojo, Melissa Ooi, Wee-Joo Chng, Sanjay De Mel

Blood (2021) 138 (Supplement 1): 3776.

https://doi.org/10.1182/blood-2021-151644

Published: 2021

Journal Articles

Clinical Application of an Ex-Vivo Platform to Guide the Choice of Drug Combinations in Relapsed/Refractory Lymphoma; A Prospective Study

Blood (2021) 138 (Supplement 1): 720.

https://doi.org/10.1182/blood-2021-149331

Published: 2021

Journal Articles

Single Cell Multi-Omic Profiling of Multiple Myeloma with t(4;14) Finds an Immune Microenvironment Gene Signature That Correlates with Clinical Outcomes

Sanjay De Mel, Jonathan Adam Scolnick, Chern Han Yong, Xiaojing Huo, Stacy Xu, Cinnie Yentia Soekojo, Fangfang Song, Melissa Ooi, Wee Joo Chng

Blood (2021) 138 (Supplement 1): 2653.

https://doi.org/10.1182/blood-2021-149107

Published: 2021

Journal Articles

Super-Enhancer-Driven PPP1R15B As an Oncogenic and Potential Therapeutic Target in Multiple Myeloma

Sinan Xiong, Jianbiao Zhou, Tze King Tan, Sabrina Hui-Min Toh, Kalpnaa Balan, Yunlu Jia, Tae-Hoon Chung, Takaomi Sanda, Wee Joo Chng

Blood (2021) 138 (Supplement 1): 2209.

https://doi.org/10.1182/blood-2021-149006

Published: 2021

NARROW

Core-binding factor fusion downregulation of ADAR2 RNA editing contributes to AML leukemogenesis

A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia

Systematic Functional Characterization for Loss of Function Events Cooperating with TP53 Loss in High-Risk 17p13(del) Multiple Myeloma

Elucidating the Role of ADAR1 in Regulating Immunotherapeutic Response in Multiple Myeloma

Daratumumab in Multiple Myeloma - a Nationwide Real-World Experience from Singapore

Single Cell Multi-Omic Profiling of Multiple Myeloma with t(4;14) Identifies a T-Cell Population That Correlates with Clinical Outcomes

How Does Treatment Intolerance Affect Survival in Patients with Multiple Myeloma (MM)?

Myeloma Treatment Patterns and Clinical Outcomes in the Asia-Pacific: Updated Results from the Asia-Pacific Myeloma and Related Diseases Registry

Pre-Clinical Evaluation of a Camsirubicin Analog Mnpr-202 in Diffuse Large B Cell Lymphoma

A Non-Coding Variant in LOC105371512 Confers Susceptibility to Bleomycin-Induced Lung Injury

Efficacy of Frontline Treatments for Newly Diagnosed Transplant-Ineligible Multiple Myeloma, a Network Meta-Analysis

Real World Treatment Outcomes for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant in Different Income Countries within Asia Pacific Region

New immunotherapeutic target in myeloma

Evaluating Front Line Treatment Regimens for Waldenstrom Macroglobulinaemia: A Systematic Review and Meta-Analysis

Mapbatch: Conservative Batch Normalization for Single Cell RNA-Sequencing Data Enables Discovery of Rare Cell Populations in a Multiple Myeloma Cohort

Single-Cell Multi-Omic Analysis Uncovers Comprised Immune Function and Primary Resistance Mechanism in Acute Myeloid Leukemia

Lenalidomide Compared to Ixazomib Maintenance in Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis

Clinical Application of an Ex-Vivo Platform to Guide the Choice of Drug Combinations in Relapsed/Refractory Lymphoma; A Prospective Study

Single Cell Multi-Omic Profiling of Multiple Myeloma with t(4;14) Finds an Immune Microenvironment Gene Signature That Correlates with Clinical Outcomes

Super-Enhancer-Driven PPP1R15B As an Oncogenic and Potential Therapeutic Target in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only